FDA Grants NeuroVive’s KL1333 Orphan Drug Status for Treatment of Mitochondrial Diseases
Investigational compound KL1333 was granted orphan drug status by the U.S. Food and Drug Administration for the treatment of inherited mitochondrial respiratory chain diseases, NeuroVive Pharmaceutical AB recently announced. The designation is a promising step for NueroVive’s KL1333 program because it will provide extra support from the FDA, including regulatory and…